Hyoscine ButylbromideThird Party Manufacturing in India

Hyoscine Butylbromide is a quaternary ammonium derivative of scopolamine that acts as a competitive antagonist at muscarinic cholinergic receptors in the smooth muscles of the gastrointestinal, biliary, and urinary tracts. By blocking the action of acetylcholine at M₂ and M₃ receptor subtypes, it reduces smooth muscle spasms and associated pain. Because it is a quaternary ammonium compound, hyoscine butylbromide has low lipid solubility and does not readily cross the blood-brain barrier, which means it has minimal central nervous system effects unlike scopolamine. This peripheral selectivity is a key differentiator, making it the preferred antispasmodic for abdominal cramping without sedative or cognitive side effects. It is administered orally as tablets or via injection for faster relief of acute spasms. The drug also has a mild antisecretory effect on salivary and sweat glands, but its primary therapeutic action remains spasmolysis of visceral smooth muscle.

Therapeutic Uses

Hyoscine Butylbromide is prescribed for the treatment of:

• Irritable Bowel Syndrome: Relieves abdominal cramping and pain associated with IBS and functional bowel disorders.
• Biliary Colic: Treats smooth muscle spasms in the bile ducts and gallbladder.
• Renal Colic: Used for ureteral spasm during kidney stone passage.
• Dysmenorrhea: Reduces painful menstrual cramping by relaxing uterine smooth muscle.
• Gastrointestinal Spasms: Manages acute gastric and intestinal spasms of various etiologies.

Why Manufacturers Choose Hyoscine Butylbromide

Hyoscine Butylbromide is a leading antispasmodic molecule with consistent over-the-counter and prescription demand across Indian and global markets. Its well-established safety profile and minimal central nervous system side effects make it a trusted choice for gastroenterology applications. The availability of both tablet and injection formulations provides versatility for PCD franchise partners looking to build a gastroenterology-focused portfolio.